Biotech
Commented by Carsten Mainitz on September 22nd, 2025 | 07:55 CEST
AJN Resources, TUI, Evotec: Fresh capital and insider purchases!
Fresh capital, insider purchases, or significant changes in the shareholder base can be important signals regarding future share price performance. The leverage effect of fresh capital is particularly high for smaller companies. This is because projects can be launched with manageable amounts of capital, bringing important milestones closer. However, the stock market sometimes reacts late because small or micro-caps fly under the radar of the investor community. However, it is precisely this constellation that creates good opportunities for active and vigilant investors.
Read
Commented by Armin Schulz on September 22nd, 2025 | 07:40 CEST
BioNxt Solutions: Your chance to get in early on the next biotech blockbuster
Imagine a cancer treatment that doesn't affect the whole body, but instead acts only at the tumor site. Or a treatment for multiple sclerosis that no longer needs to be swallowed, but simply dissolves under the tongue. What sounds like a dream of the future is already being pursued with full force by the German-Canadian biotech company BioNxt Solutions. The Company is developing two innovative platform technologies that aim to solve some of the biggest challenges in modern medicine. For investors, this opens up extraordinary opportunities.
Read
Commented by Fabian Lorenz on September 18th, 2025 | 07:25 CEST
Adidas to take over Puma? Evotec with insider buying! 50% upside potential with AI stock NetraMark!
Adidas and Puma caught in merger fever? A US investor brings the spectacular idea into play. Is it a means of exerting pressure on Puma's management or a real possibility? What do analysts say? Meanwhile, Evotec is sending a signal of confidence with fresh insider purchases. However, the stock is still digesting the recent revenue forecast downgrade. Could there be fresh momentum next week? In contrast, NetraMark shares offer a 50% return. For this to happen, however, the AI-driven drug development specialist must reach the analysts' price target. Operationally, there is much to be said for this, and in comparative tests, the Company has outperformed ChatGPT and DeepSeek.
Read
Commented by Armin Schulz on September 18th, 2025 | 07:15 CEST
Novo Nordisk, PanGenomic Health and Pfizer - Who are the winners of the digital health revolution?
The disruptive force of the digital health revolution is fundamentally changing the healthcare industry. Artificial intelligence, data-driven therapies, and digital diagnostics are opening up billion-dollar markets and catapulting agile players to the forefront. These pioneers are setting new standards in patient-centered care and generating exponential growth in the process. This ecosystem opens up unique opportunities for strategic investors. Today, we take a look at Novo Nordisk's restructuring, PanGenomic Health's AI-driven innovations, and the political uncertainties at Pfizer.
Read
Commented by Fabian Lorenz on September 18th, 2025 | 07:10 CEST
MAJOR DEVELOPMENTS for megatrend stocks: Rheinmetall, BioNTech, First Hydrogen
Rheinmetall is going full throttle: on land, at sea, in the air, and even in space. Its latest bombshell is the announced takeover of Lürssen's naval division. Will this provide the tailwind the stock needs to break through the EUR 2,000 mark on a sustained basis? Analysts view the transaction positively, though some cautionary voices remain. Meanwhile, a major development in Canada is boosting sentiment around First Hydrogen. North Americans aim to be at the forefront of the small modular reactors (SMRs) movement. The potential is enormous. BioNTech also holds significant promise in the fight against cancer. However, challenges have emerged - ironically in the world's largest pharma market. The US government plans to cut or even stop funding for new mRNA vaccine development. BioNTech shares reacted accordingly and may break through their sideways trend downwards.
Read
Commented by Nico Popp on September 18th, 2025 | 07:05 CEST
Understanding metabolism, generating returns: Vidac Pharma, Roche, AstraZeneca
In the search for new treatments against diseases, researchers agree on one thing: the holy grail is unlikely to be found. Instead, it is incremental improvements and combination therapies that promise progress in complex diseases such as cancer. Cell metabolism is considered a promising approach, for example, in cancer, when the metabolism of a cancer cell is disrupted, the cell dies. In this article, we present current approaches and also discuss a biotechnology company that is wholly dedicated to cellular metabolism.
Read
Commented by Carsten Mainitz on September 17th, 2025 | 07:20 CEST
Globex Mining, Deutz, Novo Nordisk – Prices are rising!
On the stock market, there is often a difference between price and value. Companies with strong assets and holdings, or those with business models that benefit from long-term trends, tend to deliver attractive returns for investors in the long run. All the better if such companies can be acquired at a favorable price - one that lies below the fair value of their shares.
Read
Commented by Stefan Feulner on September 16th, 2025 | 07:25 CEST
Broadcom, NetraMark, Adobe – The AI wave continues to roll inexorably forward
Artificial intelligence is more than just hype; it is becoming the central driver of innovation in our time. Whether in industry, medicine, mobility, or finance, this technology is changing processes, increasing efficiency and creating new business models in almost all sectors. Companies that embrace AI early on secure clear competitive advantages. At the same time, a future market with enormous potential is opening up for investors. However, despite the rosy outlook, stock picking is also required here, as many companies are significantly overvalued.
Read
Commented by Fabian Lorenz on September 16th, 2025 | 07:00 CEST
Hot Stock shakes up Big Pharma! BioNxt Solutions aims to replace Ozempic weight loss injection!
BioNxt is currently shaking up Big Pharma. The announcement that it plans to replace the Ozempic weight loss injection with an oral dissolvable film is once again fueling speculation about the share price. Just like in the multiple sclerosis space, the Company aims to disrupt a billion-dollar obesity market. Further exciting operational news is expected in the coming months. Key patents are already in place. With a market capitalization of around CAD 100 million, the Canadian-German life sciences company is far from expensive – even for Big Pharma. The major corporations will undoubtedly be watching BioNxt's development very closely in the coming months. Until then, the stock is likely to trade significantly higher.
Read
Commented by Nico Popp on September 15th, 2025 | 07:15 CEST
No more diet injections! Innovations in weight loss drugs: BioNxt Solutions, Merck & Co., Novo Nordisk
As recently reported by the United Nations Children's Fund (UNICEF), for the first time, more children worldwide are obese than underweight. While this is a great success in the fight against hunger, it also poses new risks. Severe overweight in childhood leads to obesity and associated diseases in adulthood, such as cardiovascular problems and diabetes. The treatment of overweight and diabetes in children is therefore likely to play an even more significant role in the future. GLP-1 receptor agonists have been popular for several years now in the form of modern weight loss injections. With patents expiring soon, experts anticipate substantial further growth and development in this rapidly expanding market. We explain who could benefit and what the future holds for modern diet medications.
Read